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1. Introduction 
Mucins are large, highly O-glycosylated proteins that are present at the surface of most 
epithelial cells and are involved in the protection and lubrication of the epithelium (Gendler 
and Spicer 1995). The expression of mucin genes is organ-and cell-type specific. The 
increased expression and altered glycosylation of mucins influence cellular growth, 
differentiation, transformation, adhesion and immune surveillance (Hollingworth and 
swanson 2004) and are associated with the development of cancer. Mucins have been 
implicated in the biologic behavior and progression of several cancers. During 
carcinogenesis, aberrant glycosylation leads to the development of tumor subpopulations 
with different adhesion properties (Taniguchi et al. 1996; Hiraiwa et al. 1996). Alterations of 
mucins during the pathogenesis of cancer have been well documented (Hakomori et al. 
2002). The under glycosylation of mucins results in the creation of tumor associated cryptic 
carbohydrate core structures Tn, sialyl Tn and T (Taylor-Papadimitriou et al. 1999).  
The Gram-negative bacterium Helicobacter pyroli infects over 50% of the world’s 
population and causes various gastric diseases such as chronic gastritis, peptic ulcer and 
gastric cancer. Peripheral lymph node addressin (PNAd) containing 6-sulfo sialyl Lewis X-
capped O-glycans on high endothelial venule (HEV)-like vessels are closely associated with 
pathogenesis of H pyroli-related diseases. The ǂ1,4 GlcNAc-capped O-glycans expressed by 
gastric gland mucous cell-derived mucin prevents colonization of H pyroli. Thus, the 
differential expression of distinct O-glycans in stomach provides therapeutic potentialities 
based on specific carbohydrate modulation (Nakayama et al. 1999; Reis et al. 2000 and 
Kobayashi et al. 2009). 
Werther et al. (1996) examined the frequency of sialyl Tn expression and its prognostic value 
in gastric cancer by immunohistochemical analysis of 340 gastric tumors and found that 
sialyl Tn expression is a marker of gastric cancer progression suggesting that cancer 
associated mucins play a role in the malignant behavior of the tumor. Santos-Silva et al. 
(2005) have reported that polymorphism in the MUC1 tandem repeat exerts influence on the 
expression of cryptic carbohydrate core structures in gastric cancer cells and the aggressive 
gastric tumors tend to express T antigen. Immunohistochemical study of Amado et al. (1998) 
for the expression of dimeric sialyl Lewisx in 97 gastric carcinomas revealed a correlation 
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between high expression of dimeric sialyl Lewisx and venous invasion and poor outcome in 
gastric cancer patients. Petretti et al (1999) studied RNA expression of several 
glycosyltransferases in surgical specimens of gastric carcinomas and found significant 
enhancement in the expression of ST3Gal IV and FucT IV. 
A comprehensive study by Carvalho et al. (1999) on mucin expression in a panel of gastric 
carcinoma cell lines found no apparent relationship between the mucin core proteins and 
the simple mucin type or Lewisx carbohydrate antigens that are expressed in each cell line. 
Thus there exists a complexity in glycosyltransferase activities which lead to several tumor- 
associated carbohydrate structures in gastric carcinoma.  
 A comparative study of gene-expression profiles of adenocarcinoma metastases and 
primary adenocarcinomas (Ramaswamy et al. 2003) indicated that a subset of primary 
tumors resembled metastatic tumors with respect to a gene-expression signature and that 
solid tumors carrying this gene-expression signature were most likely to be associated with 
metastasis and poor clinical outcome. These results further suggested that the metastatic 
potential of human tumors is encoded in the bulk of a primary tumor and thus challenged 
the notion that metastases arise from rare cells within a primary tumor that have the ability 
to metastasize (Poste et al. 1980). Thus, it became obvious that a very consistent change of 
some biological events in a primary tumor as opposed to the normal tissue has the 
possibility of being related to the malignant potential of the tumor. Recently, we examined 
the patterns of glycosyl- and glycan-sulfotransferase activities in several cancer cell lines and 
the resulting data strongly suggested an association of unique carbohydrate structures with 
signature potential in individual cancers (Chandrasekaran et al. 2006). The present study 
was aimed to identify the glycosyl- or sulfotransferase which exhibits the most marked and 
consistent change of activity in gastric tumorigenesis, by comparing the pattern of various 
glycosyl and glycan: sulfotransferase activities in tumorous and normal gastric tissues of 
each patient in ten gastric carcinoma cases. 
2. Materials and methods 
2.1 Tissue specimens 
Human gastric tumor specimens were obtained during surgical procedures at Roswell Park 
Cancer Institute and stored frozen within 1h at -70°C. We studied the gastric tumor as well 
as non-tumor stomach tissue specimens from the same patient in ten gastric carcinoma cases 
and, in addition, two gastric tumor specimens in which case normal stomach tissue 
specimens were unavailable. The Pathology report on the tumors is presented in Table 1 and 
Table 4.  
When the samples were collected from Pathology, a portion of the sample adjacent to that 
used for enzyme assay was fixed in formalin and embedded in paraffin. Slides were 
prepared from the paraffin blocks, and stained with hematoxylin and eosin by standard 
procedures. A board-certified pathologist studied the slides to determine the distribution of 
cell types within the tumor tissue compared to the control tissue from the same case 
(although in three cases non-tumor tissue was not available). Due to the invasiveness of the 
gastric cancer in these cases, both the tumor and the non-tumor tissue samples generally 
contained smooth muscle. The smooth muscle component existed at roughly equivalent 
percentage in the tumor sample and non-tumor control on a case by case basis sometimes 
being a little larger in either tumor or non-tumor sample. The major difference between the 
normal and tumor sample in this study was that the tumor contained malignant epithelial 
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cells, and the normal never did. With the exception of case 10, the amount of protein 
solubilized from the tumor and the corresponding non-tumor specimen by Triton X-100 did 
not vary much as evident from the values reported in Table 1. Thus, it becomes evident that 
a comparison of each glycosyltransferase and glycan:sulfotransferase activity per mg protein 
of the tissue extract between tumor and the corresponding non-tumor specimen is quite 
meaningful in understanding the quantitative change of each enzyme activity in 
tumorigenesis. 
 
Gastric 
cancer 
cases 
Tumor Site STG 
Smooth 
muscle 
(%) 
N       T 
Specimen 
Wt. (g) 
N       T 
Protein (mg) in 
Triton X-100 
solubilized 
extract /g tissue 
N          T 
1 
Overlapping 
lesion of stomach 
 30         40 3.5      1.9 52.8      67.4 
2 
Lesser curvature 
of stomach, NOS 
3A 30          50 1.9      2.5 58.5     53.6 
3 
Lesser curvature 
of stomach, NOS 
3A 20          30 4.2      1.9 54.6      42.2 
4 
Lesser curvature 
of stomach, NOS 
2 N/A      70 6.0      1.0 60.0      41.0 
5 Gastric antrum 3A 20          20 0.8      0.8 80.0       80.0 
6 Gastric antrum 1B 20          30 0.8      0.6 60.4       67.5 
7 Gastric antrum 2 10            0 1.7      0.5 52.4       82.8 
8 Body of stomach 3A 10          10 0.6      2.1 68.9       80.2 
9 Body of stomach 1B 20          10 0.6      2.0 52.9       86.9 
10 Cardia, NOS 3A 40          30 1.9      2.3 112.0       23.5 
11 Stomach, NOS 4 N/A      60 N/A    3.6                58.3 
12 
Lesser curvature 
of stomach, NOS 
 N/A        0 N/A    3.5                76.8 
N; Non-tumor gastric tissue; T:  Tumor gastric tissue N/A Not available 
Table 1. The cancer site, stage and the details of the gastric tumor and non-tumor specimens 
from 12 patients 
2.2 Acceptor compounds 
The synthetic compounds used as acceptors in this study have already been used in our 
earlier studies (Chandrasekaran et al. 1995; 1996; 2001; 2004; 2005; 2006) and, thus, are well-
documented acceptors for measuring the reported enzyme activities. 
2.3 Processing of tissue specimens 
The tissues were homogenized at 4°C with 4 volumes of 0.1 M Tris Maleate pH 7.2, 0.1% 
NaN3 using kinematica. After adjusting the concentration of TritonX-100 to 2%, these 
homogenates were mixed in the cold room for 1h using Speci-Mix (Thermolyne) and then 
centrifuged at 20,000g for 1h at 4°C. The clear fat-free supernatant was stored frozen at -20°C 
until use. Aliquots of 10µL from this extract were used in assays run in duplicates.  
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2.4 Enzyme assays 
Glycosyltransferase activity in tumor extract was determined by mixing the tumor extracts 
with acceptor and radiolabeled monosaccharide donor under the reaction conditions 
detailed below, followed by separation of unreacted donor from the radioactive product 
using anionic or hydrophobic chromatography. In all cases, the radioactive content of 
isolated products was determined by using 3a70 scintillation cocktail (research Products 
International, Mount Prospect, IL) and a Beckman LS9000 scintillation counter. Controls for 
each assay contained the reaction mixture with everything except the acceptor. Radioactivity 
of control was subtracted from that of product to obtain the results presented in the Tables. 
All assays were run in duplicate. Results from duplicate runs did not vary by more than 5%. 
The following are the conditions for individual enzymatic assays. Reaction temperature in 
all cases was 37°C.  
2.5 Sialyltransferase 
ǂ2,3- and ǂ2,6 sialyltransferase (ST) assay reactions proceeded for 2h in a mixture containing 
100mM sodium cacodylate buffer (pH 6.0), 7.5mM acceptor, CMP-[9-3H] NeuAc (typically 
0.2μCi) and 10μl tumor extract in a total volume of 20μl (Chandrasekaran et al. 1995, 2005). 
2.6 Gal/GalNAc transferases 
ǃGlcNAc: ǃ1,4Gal-T and ǂGalNAc:ǃ1,3Gal-T assay mixtures in duplicate contained 0.1M 
Hepes-NaOH pH 7.0, 7mM ATP, 20mM Mn acetate, 1mM UDP-Gal. UDP [14C] Gal (0.05μCi; 
327mCi/mmol; Amersham), 0.5mM acceptor (unless otherwise stated) and 10μl tumor 
extract in a total volume of 20μL (Chandrasekaran et al. 2001). It was incubated for 4h;  
ǃGlcNAc:ǃ1,4GalNAc-T assay mixtures in duplicate contained 0.1M Hepes-NaOH ph7.0, 
7mM ATP, 20mM Mn acetate, UDP [3H] GalNAc (0.20μCi; 7.8Ci/mmol: New England 
Nuclear Corp.)  7.5mM acceptor and incubated for 4h (Chandrasekaran et al. 2001).  
2.7 Fucosyltransferases 
ǂ1,2,  ǂ1,3- , ǂ1,4-fucosyltransferase  and FT VI  assay reactions were carried out for 2h in a 
reaction mixture containing 50mM Hepes buffer (pH 7.5), 5mM MnC12, 7mM ATP, 3mM 
NaN3, 3mM synthetic acceptor, 0.05μCi GDP-[14C]Fuc (290mCi/mmol) and 10μl tumor 
extract in a total volume of 20μl (Chandrasekaran et al. 1996).   
2.8 Glycan: sulfotransferases 
Sulfotransferase (Sulfo-T) assay reactions took 2h and required a mixture containing 100mM 
Tris-Maleate (pH 7.2), 5mM Mg Acetate, 5mM ATP, 10mM NaF, 10mM BAL, 7.5mM 
acceptor, 0.5μCi of [35S]PAPS (specific activity 2.4Ci/mmol) and 10μl of tumor extract in a 
total volume of 30μl (Chandrasekaran et al. 2004).  
2.9 Chromatographic methods 
Dowex-1-Cl or Sep-Pak C18 cartridges were used to isolate radiolabeled product from the 
reaction mixture. For Gal-T, GalNAc-T and FT assays, the incubation mixture was diluted 
with 1ml water and passed through a 1ml bed volume of Dowex-1-Cl column 
(Chandrasekaran et al. 1996, 2001). The column was washed twice with 1ml water. The 
breakthrough and the water wash contained the [14C]-galactosylated or [14C]-fucosylated 
products formed with neutral acceptors. 3ml of 0.1M NaCl was used to obtain [14C]-
fucosylated products from sialylated acceptors after water elution. For sialyltransferase 
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assays, the radioactive products from benzylglycosides were separated by hydrophobic 
chromatography on Sep-Pak C18 cartridge (Water, Milford, MA), and elution of the product 
was done with 3ml methanol (Chandrasekaran et al. 2005; Palcic et al. 1998). For 
sulfotransferase assays, elution of the [35S]-sulfated compound from Dowex-1-Cl column 
could be achieved by 3ml of 0.2M NaCl (Chandrasekaran et al. 2001). 
2.10 Effect of divalent cations on gastric tumor Gal: 3-O-sulfotransferase activity 
For seeing the effect of divalent cations on Gal: 3-O-sulfotransferase activity the incubation 
mixture contained varying concentration (1-50mM) of Mg acetate, Mn acetate or Ca acetate 
under the standard incubation conditions. Gal3Sulfo-T4 activity was assayed using 3-O-Me 
Galǃ1, 4 GlcNAcǃ1,6(Galǃ1,3)GalNAcǂ-O-Bn as the acceptor. Gal3Sulfo-T2 activity   was 
measured with the acceptor Galǃ1, 4 GlcNAcǃ1, 6(3-O-MeGalǃ1, 3)GalNAcǂ-O-Bn. 
2.11 N-Acetylglucosaminltransferase assay 
The reaction mixture (30μl) contained 5mM acceptor, 70 mM Hepes-NaOH pH7.0, 7mM 
GlcNAc 1, 5 lactone, 14mM Mn acetate, 5mM ATP, 2mM NaN3, 0.2μCi UDP-[6-3H] GlcNAc 
(NEN-Dupont) and 15μl tumor extract and incubated for 4h at 37°C. The radioactive 
products from benzyl glycosides were separated by hydrophobic chromatography on Sep-
Pak C18 cartridge and from allyl glycoside by Biogel P2 column chromatography as 
described above. 
2.12 β N-acetylhexosaminidase treatment 
10 μl of the [6-3H] N-acetyl glucosamine containing products were incubated at 37°C for 20h with 
0.1 unit of this enzyme as recommended by supplier (GLYKO) in a reaction volume of 20μl.  
2.13 β1, 3Galactosidase (recombinant enzyme from calbiochem) treatment 
10 μl of the [6-3H] N-acetyl glucosamine containing product from Galǃ1, 3 (GlcNAc ǃ 1, 6) 
GalNAc ǂ O-Al was mixed with 10μl of 0.1M citrate buffer-0.1% BSA pH 5.0 and 10μl (20 
mU) recombinant enzyme and incubated at 37°C for 20h. 
2.14 Lectin-agarose chromatography 
PNA-agarose (Sigma), ConA-agarose (Sigma) and GSL II-agarose (Vector) columns of 5 ml 
bed volume were used under conditions as recommended by suppliers. 
2.15 Thin layer chromatography 
TLC was carried out on Silica gel GHLF (250 μm scored 20x20cm; Analtech, Newark DE). 
The solvent systems A [1 propanol/NH4OH/H2O (12/2/5 V/V)] and B [n-butanol/acetic 
acid/H2O (3/2/1)] were used. The acceptor compounds were located on the plates by 
spraying with sulfuric acid in ethanol and heating at 100°C. The radioactive products were 
located by scraping 0.5cm width segments of silica gel and soaking them in 2 ml water in 
vials followed by liquid scintillation counting. 
3. Results 
3.1 Non-reducing terminal of complex carbohydrate chains 
Several glycosyltransferases and glycan-sulfotransferases act on the non-reducing terminal 
of mucin Core2 tetra-and tri-saccharides and Globo backbone unit of gangliosides, core 1 
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disaccharide and Asparagine  linked complex carbohydrate chains terminating in Gal 
residues,  leading to a complexity of cancer-associated terminal glycan structures as shown 
in Table 2. Hence, we examined the levels of many of these enzyme activities in gastric 
tumor tissue as well as non-tumor gastric tissue of the same patient in ten gastric cancer 
cases for identifying any significant consistent change in any of these enzyme activities in 
gastric cancer. The specific acceptor compounds used in the present study for assaying the 
enzymes are reported in Table 3. The results on various enzyme levels are presented in 
Tables 4 and 5. 
 
Carbohydrate chain terminal Modifying  glycosyl-and sulfo-
transferases 
1. *GlcNAcǃ1,6(Galǃ1,3)GalNAcǂ-O-Ser/Thr 
(mucin core2 trisaccharide) 
ǃ1,3Gal/GalNAcTs; FTVI;  
ǃ1,4Gal/GalNAcTs;  
GlcNAc6SulfoT 
2.  
a) *Galǃ1,4GlcNAcǃ1,6(Galǃ1,3)GalNAcǂ-O-Ser/Thr 
(mucin core2 tetrasaccharide) 
b) Asparagine  linked complex carbohydrate chains 
terminating in *Gal residues 
 
Gal3SulfoT2;  Gal3SulfoT3 
ST3Gal  III; ST3Gal  IV 
ǂ1,2-FT; ǂ1,4-GlcNAcT 
ǃ1,3-GlcNAcT 
3. 
a) Galǃ1,4GlcNAcǃ1,6(*Galǃ1,3)GalNAcǂ-O-Ser/Thr 
b) GlcNAcǃ1,6(*Galǃ1,3)GalNAcǂ-O-Ser/Thr 
c) *Galǃ1,3 GalNAcǂ-O-Ser/Thr  
(mucin core1 disaccharide) 
d) *Galǃ1,3 GalNAcǃ 1,3 Galǂ-O-R  
(Globo unit of gangliosides) 
 
Gal3SulfoT4; ST3Gal  I 
ST3Gal  II; ǂ1,2-FT 
ǂ1,4-GlcNAcT 
ǃ1,3-GlcNAcT 
 
* Denotes the terminal unit utilized by the enzyme to transfer monosaccharide or sulfate 
Table 2. Glycosyl-and sulfo-transferases involved in carbohydride chain terminal 
modification 
3.2 Fucosyltransferase activities in gastric carcinoma 
ǂ1,3-FT contributed the major FT activity in both normal and tumor specimens in all cases. 
In nine cases, the tumor specimens as compared to normal (with the exception case 10) 
contained lower ǂ1,3-FT activity (a decrease of 10-60%). There was a marked reduction (40-
90%) of ǂ1, 2-FT activity in seven cancer cases (2, 3, 4, 5, 6, 7 and 9). Thus, it is interesting to 
note that a decrease of ǂ 1, 3- and ǂ 1, 2- FT activities occurred in the same specimens. On 
the other hand, ǂ1,4-FT activity and FTVI activity were present in increased level in the 
same five cancer cases (1, 3, 4, 7 and 10) and in decreased level in the same five cases (2, 5, 6, 
8 and 9). Four tumor specimens (cases 7, 4, 1 and 10) which include two Signet ring cell CA 
and two mucin producing adenocarcinoma exhibited high elevation of FTVI activity (8.9, 
10.5, 51.4 and 199.5 fold respectively) as compared to the corresponding normal specimen. 
Further, a highly noteworthy finding is that the gastrointestinal stromal tumor specimen 
(case 12) was distinct in having a low level of ǂ1, 3-FT activity and negligible amounts of ǂ1, 
4-FT, ǂ1,2-FT and FTVI activities as compared to other tumor specimens. 
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Glycosyl- or Sulfo-transferases    Acceptors  
 Fucosyltransferases: 
                ǂ 1, 2-FT 
                ǂ 1, 3-FT 
                ǂ 1, 4-FT 
                FTVI 
 
Gal ǃ-O-Bn 
2-O-Me Gal ǃ 1, 4 GlcNAc 
2-O-Me Gal ǃ 1, 3 GlcNAc 
GlcNAc ǃ 1, 4 GlcNAc ǃ-O-Bn 
Sialyltransferases: 
ST3(O) 
ST3(N) 
ST6(N) 
3-O-Me Gal ǃ 1, 4 GlcNAc ǃ 1, 6 (Gal ǃ 1, 3) GalNAc 
ǂ-O-Bn 
2-O-Me Gal ǃ 1, 3 GlcNAc ǃ-O-Bn 
Gal ǃ 1, 4 GlcNAc ǃ 1, 6 (3-O-Me Gal ǃ 1, 3) GalNAc 
ǂ-O-Bn [corrected for ST3(N) activity] 
 
ǃ Gal/GalNAc transferase: 
ǃ 1, 4 Gal-T 
ǃ 1, 4 GalNAc-T 
ǂ GalNAc: ǃ 1, 3 Gal-T 
3-O-Me Gal ǃ 1, 3 (GlcNAc ǃ 1, 6) GalNAc ǂ-O-Bn 
3-O-Me Gal ǃ 1, 3 (GlcNAc ǃ 1, 6) GalNAc ǂ-O-Bn 
4-Fluoro GlcNAc ǃ 1, 6 GalNAc ǂ-O-Bn 
Glycan: Sulfotransferases 
Gal 3 Sulfo-T2 
Gal 3 Sulfo-T4 
GlcNAc 6 Sulfo-T 
Gal ǃ 1, 4 GlcNAc ǃ 1, 6 (3-O-Me Gal ǃ 1, 3) GalNAc 
ǂ-O-Bn 
3-O-Me Gal ǃ 1, 4 GlcNAc ǃ 1, 6 (Gal ǃ 1, 3) GalNAc 
ǂ-O-Bn 
GlcNAc ǃ 1, 3 Gal ǃ 1, 4 Glc 
Table 3. Specific acceptors for measuring Glycosyl- and Sulfo- transferase activities in gastric 
tumor and non-tumor specimens 
3.3 Sialyltransferase activities in gastric carcinoma 
ST3 (O) activity, which forms 3'-sialyl T hapten (NeuAcǂ2, 3Galǃ1, 3GalNAcǂ) was the 
predominant sialyltransferase activity in all gastric tissue specimens. This activity increased 
(1.7-172.0 fold) in six (cases 2, 3, 4, 6, 9 and 10) and decreased in four (cases 1, 5, 7 and 8) 
gastric tissue specimens. ST6(N) activity synthesizing 6'-LacNAc type 2 unit 
(NeuAcǂ2,6Galǃ1,4GlcNAcǃ-) ranged 4% - 78% of the ST3(O) activity in the tumor tissue 
specimens studied and ST3(N) activity forming 3'-sialyl LacNAc was even far less than 
ST6(N) activity. Three out of four tumor specimens from Signet ring cell carcinoma (cases 2, 
3 and 4) and three out of five tumor specimens from adenocarcinoma (cases 6, 9 and 10) 
showed an increased level of ST3 (O) activity. Two cases of Signet ring cell CA (1 and 3) and 
three cases of adinocarcinoma (7, 8 and 9) showed significant ST6 (N) activity in the range 
8.2 – 78.0% of ST3 (O) activity. 
3.4 β-GlcNAc : β1,4-Gal/GalNAc and α-GalNAc : β1,3-Gal transferase activities in 
gastric carcinoma 
Three tumor specimens (cases 3, 4 and 10) while exhibiting an increase in ǃ1, 4Gal-T activity, 
other tumor specimens contained lower level of this activity than the corresponding normal 
specimens. Six tumor specimens (cases 3, 4, 5, 6, 8 and 10) showed an increased level of ǃ1, 
4GalNAc-T activity. It is remarkable that two tumor specimens (cases 5 and 6) from 
adenocarcinoma contained only 30% and 40% level of ǂ-GalNAc: ǃ1, 3Gal-T activity as 
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compared to the normal specimens. On the contrary, the tumor specimen of case 10 as 
compared to other tumor specimens had a high level of this activity, which exceeded even 
the levels of its ǃ1, 4Gal/GalNAc-T activities. The level of ǂGalNAc : ǃ1,3Gal-T activity was 
also higher than ǃ1,4Gal/GalNAc-T activity in Litinis Plastica specimen (case 11) 
 
Enzyme 
Activity 
 Glycosyltransferase activities in Tissue specimens: Incorporation 
of [14C] or [3H] monosaccharides (CPMx10-3) into the enzyme 
specific acceptor catalyzed by 1mg protein of the tissue extract 
  1 2 3 4 5 6 7 8 9 10 11 12 
Fucosyl-
transferases 
             
1,2-FT N 
T 
127.2 
111.2 
(0.9) 
146.8 
83.3 
(0.6) 
76.8 
49.0 
(0.6) 
62.9 
35.0 
(0.6) 
197.2 
16.5 
(0.1) 
109.4 
22.0 
(0.2) 
70.9 
132.1 
(1.9) 
102.7 
34.4 
(0.3) 
108.9 
62.5 
(0.6) 
19.9 
131.9 
(6.6) 
 
88.5 
 
2.5 
1,3-FT 
 
N 
T 
449.6 
390.5 
(0.9) 
494.1 
382.6 
(0.8) 
533.2 
448.3 
(0.8) 
422.2 
184.0 
(0.4) 
448.8 
180.2 
(0.4) 
428.4 
198.2 
(0.5) 
526.3 
352.8 
(0.7) 
367.8 
278.9 
(0.8) 
483.5 
328.7 
(0.7) 
166.4 
655.0 
(3.9) 
 
452.2 
 
107.0 
1,4-FT N 
T 
68.3 
193.9 
(2.8) 
9.1 
2.3 
(0.3) 
268.3 
322.6 
(1.2) 
71.5 
201.3 
(2.8) 
12.3 
0.0 
(0.0) 
405.2 
211.3 
(0.5) 
189.5 
325.6 
(1.7) 
173.6 
91.2 
(0.5) 
417.0 
294.5 
(0.7) 
18.4 
671.6 
(36.5) 
 
193.4 
 
0.9 
FT-VI N 
T 
3.1 
159.2 
(51.4) 
138.6 
60.6 
(0.4) 
42.7 
51.7 
(1.2) 
1.5 
15.8 
(10.5) 
16.7 
1.2 
(0.1) 
137.9 
2.7 
(0.0) 
13.6 
121.0 
(8.9) 
5.4 
3.8 
(0.7) 
227.0 
181.7 
(0.8) 
0.8 
159.6 
(199.5) 
 
90.5 
 
0.8 
Sialyl-
transferases 
             
2,3(O)ST N 
T 
184.5 
53.8 
(0.3) 
54.4 
145.1 
(2.7) 
180.4 
309.0 
(1.7) 
15.6 
122.7 
(7.9) 
234.2 
155.2 
(0.7) 
104.2 
240.3 
(2.3) 
379.7 
83.3 
(0.2) 
306.5 
245.1 
(0.8) 
148.6 
308.2 
(2.1) 
1.9 
326.8 
(172.0) 
 
114.0 
 
91.9 
2,3(N)ST N 
T 
2.1 
3.1 
(1.5) 
1.9 
4.0 
(2.1) 
0.7 
2.5 
(3.6) 
0.0 
0.0 
(0.0) 
1.1 
1.6 
(1.5) 
1.7 
2.3 
(1.4) 
0.6 
4.2 
(7.0) 
2.6 
2.2 
(0.8) 
3.6 
3.8 
(1.1) 
0.4 
7.1 
(4.3) 
 
1.1 
 
2.7 
2,6(N)ST N 
T 
0.4 
32.9 
(82.2) 
15.4 
8.3 
(0.5) 
24.5 
25.2 
(1.0) 
0.0 
7.3 
(7.3) 
16.2 
6.4 
(0.4) 
48.3 
11.9 
(0.2) 
40.5 
65.0 
(1.6) 
8.3 
38.4 
(4.6) 
50.1 
41.5 
(0.8) 
0.0 
0.0 
(0.0) 
 
8.7 
 
8.2 
Gal/GalNAc 
transferases 
             
ǃ1,3 Gal-T N 
T 
36.6 
43.3 
(1.2) 
34.8 
44.1 
(1.3) 
67.2 
65.9 
(1.0) 
25.6 
31.6 
(1.2) 
70.2 
19.4 
(0.3) 
102.0 
36.3 
(0.4) 
88.1 
138.1 
(1.6) 
98.9 
83.0 
(0.8) 
110.6 
166.4 
(1.5) 
39.7 
244.9 
(6.2) 
 
103.3 
 
23.8 
ǃ1,4 Gal-T N 
T 
172.2 
111.6 
(0.6) 
167.8 
151.9 
(0.9) 
255.3 
403.9 
(1.6) 
113.2 
124.1 
(1.1) 
232.2 
199.0 
(0.9) 
275.0 
258.4 
(0.9) 
362.5 
211.4 
(0.6) 
229.8 
205.7 
(0.9) 
264.5 
207.0 
(0.8) 
26.7 
161.9 
(6.1) 
 
92.9 
 
62.3 
ǃ1,4 GalNAc-T N 
T 
51.7 
27.2 
(0.5) 
44.3 
38.1 
(0.9) 
36.0 
50.5 
(1.4) 
12.2 
25.8 
(2.1) 
36.8 
44.0 
(1.2) 
38.5 
43.9 
(1.1) 
39.7 
32.4 
(0.8) 
37.9 
40.3 
(1.1) 
74.8 
28.7 
(0.4) 
15.3 
61.0 
(4.0) 
 
28.9 
 
10.1 
N: Non-tumor gastric tissue; T: Tumor gastric tissueValues in parentheses indicate fold of enzyme 
activity in tumor with respect to the normal 
Table 4. The levels of glycosyltransferase activities in human gastric non-tumor and tumor 
specimens 
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Gastric 
cancer 
cases 
Tumor Histology 
Differen- 
tiation 
 Sulfotransferase activities in tissue 
specimens: Incorporation of 35S-sulfate 
(CPMx10-3) into enzyme specific acceptors 
catalyzed by 1mg protein of the tissue 
extract 
Gal3sulfo T2 Gal3sulfo T4 
GlcNAc6  
sulfo T  
1 Signet ring cell CA 
Krukenberg Tumor 
Poor N 
T 
    0.8         
  60.7    (75.9) 
   3.4       
  49.1    (14.4) 
 33.8      
 43.8      (1.3) 
2 Signet ring cell CA 
Krukenberg Tumor 
Poor N 
T 
    2.1         
329.0  (156.7) 
  12.9       
  91.4      (7.1) 
 19.5     
 53.7      (2.8) 
3 Signet ring cell CA, 
Krukenberg Tumor 
Poor N 
T 
  10.1 
208.1    (20.6) 
    1.8       
111.0    (61.7) 
   1.8 
   3.6      (2.0) 
4 Signet ring cell CA, 
Krukenberg Tumor 
Moderate N 
T 
    0.1         
    2.6    (26.0) 
     0.1       
     0.5     (5.0) 
   0.1 
   0.7      (7.0) 
5 Adenocarcinoma 
nos 
Poor N 
T 
    1.1         
  11.7    (10.6) 
   27.8       
   75.8     (2.7) 
 31.1 
 49.8      (1.6) 
6 Adenocarcinoma 
nos 
Poor N 
T 
    1.4         
    2.6      (1.9) 
     6.7       
   34.3     (5.1) 
   6.0      
   3.3      (0.6)   
 7 Mucin producing 
adenocarcinoma 
Poor N 
T 
    0.3         
    2.1      (7.0) 
     0.4       
   59.6 (149.0)  
   1.9      
   5.2       (2.7) 
8 Adenocarcinoma 
nos 
Moderate N 
T 
    1.3         
    2.7      (2.1) 
     0.7         
     2.3     (3.3) 
   2.9 
   4.1       (1.4) 
9 Adenocarcinoma 
nos 
Moderate N 
T 
    0.4         
    3.3      (8.3) 
     7.1         
   19.8     (2.4) 
   1.9 
  15.3      (8.1) 
10 Mucin producing 
adenocarcinoma 
Poor N 
T 
    0           
    1.4      (1.4) 
     0.2         
   12.3   (61.5) 
    2.3 
  86.3    (37.5) 
11 Litinis Plastica Poor  
T 
              
    2.3 
              
   56.2   
              
  58.3 
12 Gastrointestinal 
stromal sarcoma 
Non-
epithelial  
Poor 
 
T 
              
    1.1 
              
     4.6    
 
  76.8 
N: Non-tumor gasrteic tissue; T: Tumor gastric tissue Values in parentheses indicate fold of enzyme 
activity in tumor with respect to the normal 
Table 5. The levels of sulfotransferase activities in human gastric non-tumor and tumor 
specimens 
3.5 Glycan: Sulfotransferase activities in gastric carcinoma 
Both Gal3Sulfo-T4 activity specific for Galǃ1, 3GalNAcǂ- and Gal3Sulfo-T2 activity utilizing 
mainly Galǃ1,4GlcNAcǃ- were found, respectively, at 2.4→61.7 fold and 1.7→156.7 fold 
elevated level in all the gastric tumor specimens studied. On the other hand, an increased 
level of GlcNAc6-Sulfo-T activity was also evident but to a lesser extent in nine gastric 
tumor specimens. Five tumor specimens, all from adinocarcinoma (cases 5, 6 7, 9 and 10) 
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contained predominantly Gal3Sulfo-T4 while Gal3Sulfo-T2 dominated in three specimens of 
Signet ring cell CA(cases 1, 2 and 3). 
3.6 The identity of Gal: 3-O-Sulfo transferases in human gastric tumor specimens 
Acceptor specificities:  A consistent marked elevated Gal: 3-O-Sulfotransferase activities in 
gastric tumors prompted us to establish further the identity of these enzymes with the known 
cloned Gal3Sulfotransferases (Chandrasekaran et. al. 2004). We studied four tumor specimens 
(cases 2, 3, 6 and 7) for acceptor specificities and the results are presented in Table 6.  
 
 
Table 6. Establishing the identity of Gal : 3-O-Sulfotransferases in Human Gastric Tumor 
Specimens 
The values in parentheses are the actual CPM designated as 100% for the acceptor Galǃ1, 
3GalNAcǂ-O-Al in the cases 6 and 7 and for the acceptor Galǃ1,4GlcNAc in the cases of 2 
and 3 
Gal3Sulfo-Ts of tumor specimens from cases 2 and 3 showed low activity towards Galǃ1, 
3GalNAcǂ-O-Al and that from cases 6 and 7 very low activity towards Galǃ1, 4GlclNAc. 
Tumor specimens 6 and 7 contained mostly Gal3Sulfo-T4 (Chandrasekaran et. al. 2004). 
Gal3Sulfo-Ts of tumor specimens 2 and 3 were found to be less active towards Fetuin 
triantennary asialo glycopeptides, which was established as the best acceptor in our earlier 
studies for Gal3Sulfo-T3 (Chandrasekaran et. al. 2004). Further, the above enzymes were 
very active towards Galǃ1, 3GalNAcǃ1, 3Galǂ-O-Me whereas Gal3Sulfo-T3 showed very 
low activity towards this acceptor.  Gal3Sulfo-Ts of tumor specimens 2 and 3 were found to 
have the identity of cloned Gal3Sulfo-T2 (Chandrasekaran et. al. 2004). 
Influence of divalent metal ions (see Fig 1):  None of the divalent metal ions Ca2+, Mn2+ and 
Mg2+ had any significant stimulating effect on Gal3Sulfo-T of tumor specimen 7. In fact, a 
gradual decline in enzyme activity was noticed upon increasing the concentration of Mn2+ in 
the reaction mixture. Thus, this enzyme resembled Gal3Sulfotransferase from breast tumor 
(Chandrasekaran et. al. 1997) as well as the cloned Gal3Sulfo-T4 (Chandrasekaran et. al. 
2004). On the other hand, the metal ions Ca2+, Mn2+ and Mg2+ stimulated the activity of 
tumor specimen 3. Mn2+ stimulated the activity between 5-20mM and then the activity 
decreased reaching the initial level at 50mM. This pattern of influence by Mn2+ on the 
activity was quite similar to that of Gal3Sulfotransferase from colon tissue (Chandrasekaran 
et. al. 1997) and cloned Gal3Sulfo-T2 (Chandrasekaran et. al. 2004). On the contrary, the 
activity of cloned Gal3Sulfo-T3 was stimulated by Mn2+ reaching the maximum at 40-50mM 
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(Chandrasekaran et. al. 2004). Thus, Gal3Sulfo-T of tumor specimen 7 was similar to 
GalSuflo-T4 and that of tumor specimen 3 closely resembled Gal3Sulfo-T2. 
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A. Case 7 tumor specimen; B. Case 3 tumor specimen ● Mn;娟 Mg; ○ Ca 
Fig. 1. Influence of divalent metal ions on gastric tumor Gal3 Sulfotransferase activities.  
3.7 Identification of human gastric tissue α- GlcNAc transferase acting on terminal 
GlcNAc residue 
The present investigation identified two N-acetylglucosaminyltransferase activities in 
gastric tissues using mucin core 2 tri- and tetra-saccharides as acceptors as reported in Table 
7. An increased level (1.5-8.5 fold) of GlcNAc transferase activity on mucin core 2 
tetrasaccharide was observed in three gastric tumor specimens as compared to that of the 
corresponding non-tumor specimens. Further, the level of this enzyme is about two-fold as 
compared to the corresponding activity of the other enzyme. The linkages of [6-3H] GlcNAc 
residues attached to mucin core 2 tri- and tetra-saccharides were further examined by 
utilizing TLC and lectin-agarose chromatography techniques (see sections 3.8 and 3.9). 
 
 
 
Gastric 
cancer 
cases 
 Incorporation [6-3H] GlcNAc (CPM x 10-3) catalyzed by 1 mg protein of 
the tissue extract 
 
Gal ǃ 1, 3 (GlcNAc ǃ 1, 6)  
GalNAc ǂ-O-Al 
 
Gal ǃ 1, 3 (Gal ǃ 1, 4 GlcNAc ǃ 1, 6)  
GalNAc ǂ-O-Bn 
  1 N 
T 
 5.9 
 5.8 
 9.8 
14.4 
  2 N 
T 
 8.4 
 6.8 
18.4 
24.5 
  5 N 
T 
15.7 
  5.2 
27.2 
26.7 
10 N 
T 
  2.1 
15.0 
  2.7 
23.0 
11 T  7.0 16.4 
Table 7. The levels of human gastric tissue N-Acetylglucosaminyltransferase activities 
towards mucin core 2 tri-and tetra-saccharides 
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3.8 TLC studies 
Fig 2 A (lanes A, B, C and D respectively) shows the mobilities (solvent system A) of the 
acceptor 3-O-Me Gal ǃ 1, 3 (GlcNAc ǃ 1, 6) GalNAcǂ-O-Bn, the [6-3H] GlcNAc containing 
product, [6-3H] GlcNAc containing product incubated with and without ǃ-N-acetyl 
hexosaminidase (Jack bean). Lanes B, C and D show that the radioactive products have the 
same mobility. It is evident from these results that ǃ-N-acetyl hexosaminidase (Jack bean) 
was not able to hydrolyze the [6-3H] GlcNAc containing product. Fig 2 B (lanes A and 
B)shows the mobilities (solvent system B) of 3-O-Me Gal ǃ 1, 3 (GlcNAc ǃ 1, 6) GalNAcǂ-O-
Bn and 3-O-Me Gal ǃ 1, 3 (Gal ǃ 1, 4 GlcNAc ǃ 1, 6) GalNAcǂ-O-Bn. Lane c shows the 
mobilities of 3-O-Sulfo Gal ǃ 1, 3 (Gal ǃ 1, 4  GlcNAc ǃ 1, 6) GalNAcǂ-O-Bn and Std. 
GlcNAc. Lanes D, E and F show respectively the mobilities of [6-3H] GlcNAc containing 
product from 3-O-Me Gal ǃ 1, 3 (GlcNAc ǃ 1, 6) GalNAcǂ-O-Bn,  3-O-Me Gal ǃ 1, 3 (Gal ǃ 1, 
4, GlcNAc ǃ 1, 6) GalNAcǂ-O-Bn and 3-O-Sulfo Gal ǃ 1, 3 (Gal ǃ 1, 4, GlcNAc ǃ 1, 6) 
GalNAcǂ-O-Bn  after treatment with ǃ-N-acetyl hexosaminidase (Jack bean). It is clear that 
[6-3H] GlcNAc was released only from the radioactive products arising from the last two 
acceptors (Lanes E and F) indicating that [6-3H] GlcNAc is ǃ linked to mucin core 2 
tetrasaccharide . Fig 2 C lane A shows the mobilities (Solvent system B) of acceptor Gal ǃ 1, 
3 (GlcNAc ǃ 1, 6) GalNAcǂ-O-Al and Std. GlcNAc. Treatment with recombinant ǃ 1, 3 
Galactosidase resulted in the removal of Gal as evident from the faster mobility of the 
radioactive product (lane C). ǃ-N-Acetylhexosaminidase (Jack bean) did not act on the 
radioactive product (compare lanes E and F). 
3.9 Lectin-agarose chromatography 
The primary sugar specificity of PNA is Gal linked ǃ 1, 3to GalNAc. ConA binds Man and 
Glc and GSL II binds terminal GlcNAc but these lectins have additional structural 
requirements for binding. Fig 3 shows PNA-agarose  affinity chromatography of [6-3H] 
GlcNAc containing product from Gal ǃ 1, 3 (GlcNAc ǃ 1, 6) GalNAcǂ-O-Al. More than 90% 
of the product binds to this column as shown in Fig 3 A indicating that [6-3H] GlcNAc is not 
transferred to the Gal terminal. The radioactive product after recombinant ǃ 1, 3 
Galactosidase treatment was subjected to PNA-agarose affinity chromatography and it 
showed > 90% non-binding to this column. On the contrary to these results, Nakayama et al. 
(1999) without showing data just mentioned in their paper that their cloned human ǂ 1, 4 N-
acetylglucosaminyltransferase acted only on the Gal moiety of mucin core 2 trisaccharide. 
We find that [6-3H] GlcNAc linkage to ǃ 1, 6 linked GlcNAc in mucin core 2 is completely 
resistant to Jack bean ǃ-N-acetyl hexosaminidase which has a broad specificity cleaving non-
reducing terminal ǃ 1- 2, 3, 4 or 6 linked GlcNAc and GalNAc residues (Li and Li 1970). This 
enzyme was also able to cleave very efficiently GlcNAc linked ǃ 1, 4 to GlcNAc (N, Nʹ-
Diacetylchitobiose) (Li and Li 1970). Thus GlcNAc transferred to ǃ 1, 6 linked GlcNAc has 
been found to be in ǂ-linkage. Nakayama et al. (1999) reported that ǂ 1, 4 GlcNAc-T was 
responsible for the formation of GlcNAc ǂ 1, 4 Gal ǃ-R which in turn was responsible for 
class III mucin ConA reactivity. In this connection, it is noteworthy that the present study 
found that the radioactive compound [6-3H] GlcNAc ǂ GlcNAc ǃ 1, 6 (Gal ǃ 1, 3) GalNAc ǂ-
O-Al did not bind to ConA-agarose as well as GSL II-agarose (Fig 4 A and B). After the 
removal of Gal by recombinant ǃ 1, 3 galactosidase treatment, the resulting radioactive 
compound still did not bind to GSL II-agarose (Fig 4 C). 
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A B C 
20 59 180 181 20 80 135 104 20 62 96 155 102   
19 48 110 174 19 67 115 78 19 97 62 74 106   
18 55 106 213 18 46 125 81 18 95 67 102 109   
17 62 114 147 17 72 806 433 17 98 100 119 94   
16 
 
85 154 80 16 63 2996 2503 16 114 99 83 107   
15 81 180 159 15 55 1954 2238 15 84 106 90 115   
14 527 170 208 14 63 303 414 14 83 703 219 247   
13 482 1861 1910 13 67 108 79 13 233 2942 158 265   
12 69 218 313 12 54 75 51 12 142 249 123 100   
11 50 78 121 11 48 107 52 11 95 97 114 136   
10 55 132 102 10 74 92 99 10 109 125 233 86   
9 50 66 152 9 85 134 136 9 816 400 3217 1404   
8 48 85 97 8 435 288 240 8 3550 392 997 2988   
7 54 79 106 7 512 109 98 7 287 84 109 136   
6 40 71 109 6 58 93 52 6 150 62 116 127   
5 49 97 110 5 44 108 51 5 113 84 124 137   
4 42 127 118 4 58 97 62 4 130 84 98 102   
3 49 148 108 3 47 89 47 3 94 69 102 98   
2 47 68 139 2 42 79 62 2 108 63 137 104   
1 48 114 153 1 50 115 66 1 85 72 128 121   
   A     B     C     D   A    B   C     D     E      F     A      B      C      D      E 
Fig. 2. TLC Identification of ǃGlcNAc:  ǂGlcNAc transferase activity in human gastric tumor 
Fig. 2  A (solvent system A).  
A: Acceptor compound 3-O-Me Gal ǃ 1, 3 (GlcNAc ǃ 1, 6) GalNAc ǂ-O-Bn 
B: [6-3H] GlcNAc containing product resulting from A 
C and D: B incubated with and without ǃ N-acetylhexosaminidase (Jack bean)  
Fig. 2. B (solvent system B). 
A: 3-O-Me Gal ǃ 1, 3 (GlcNAc ǃ 1, 6) GalNAc ǂ-O-Bn 
B: 3-O-Me Gal ǃ 1, 3 (Gal ǃ 1, 4 GlcNAc ǃ 1, 6) GalNAc ǂ-O-Bn 
C: 3-O-Sulfo Gal ǃ 1, 3 (Gal ǃ 1, 4 GlcNAc ǃ 1, 6) GalNAc ǂ-O-Bn and Std. GlcNAc 
D, E and F: [6-3H] GlcNAc containing products resulting from A, B and C respectively after 
ǃ N- acetylhexosaminidase(Jack bean) treatment 
Fig. 2. C (Solvent system B). 
A: The acceptor Gal ǃ 1, 3 (GlcNAc ǃ 1, 6) GalNAc ǂ-O-Al and Std. GlcNAc 
B:  [6-3H] GlcNAc containing product resulting from the acceptor in A 
C:  B after ǃ 1, 3 galactosidase (recombinant) treatment  
D and E:  B incubated with and without ǃ N- acetylhexosaminidase (Jack bean)  
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A:  [6-3H] GlcNAc containing product resulting from the acceptor Gal ǃ 1, 3 (GlcNAc ǃ 1, 6) GalNAc ǂ-
O-Al 
B:  ǃ 1, 3 galactosidase (recombinant) treated [6-3H] GlcNAc containing product 
Fig. 3. PNA-agarose affinity chromatography of [6-3H] GlcNAc containing product 
 
 
Affinity chromatography of [6-3H] GlcNAc containing product resulting from the acceptor Gal ǃ 1, 3 
(GlcNAc ǃ 1, 6) GalNAc ǂ-O-Al  on A: Con A-agarose; B: GSL II-agarose; C: GSL II-agarose after ǃ 1, 3 
galactosidase (recombinant) treatment 
Fig. 4. Chromatography on ConA-agarose and GSL II-agarose 
4. Discussion 
Many risk factors have been associated with the development of gastric cancer, and the 
pathogenesis is most likely multifactorial. One postulation on the development of this 
disease involves a succession of histologic changes that commence with atrophic gastritis, 
advance to mucosal metaplasia, and eventually result in a malignancy (Layke et al. 2004). 
Tumor development and growth can be viewed as uncontrolled tissue growth. Tumor 
growth relies on blood supply by the blood vessels (Kobayashi et al. 2003). It has been 
known that a growing tumor secretes factors that induce blood vessel growth (i.e., 
neovascularization) to support its own growth and survival (Folkman et al. 1995). A 
primary cell type of the blood vessels, especially microvessels in a tumor, is an endothelial 
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cell. Therefore, focus has been to discover factors that specifically control endothelial cell 
proliferation (Davis et al. 2003). The roles of other factors are just beginning to be 
understood (Sogn et al. 2005). The tumor microenvironment needs to be completely 
characterized for understanding its role in tumor progression and metastasis (Sogn et al. 
2005). Glycoproteins play a role in pathological processes due to immunological response to 
the altered oligosaccharides (Fukuda et al. 1996). They have roles in cell adhesion during 
inflammation and metastasis (Fukuda et al. 1996). Hence it is anticipated that glycoproteins 
may have a definite role in tumor microenvironment.  
Recently an important role for galectins in cancer micrometastasis became evident from the 
report of Khaldoyandidi, et al. (2003) that interactions between T-antigen of breast cancer 
cells and galectin-3 mediate both homotypic and heterotypic intercellular adhesion of 
metastatic breast cancer cells under conditions of flow in vitro and in vivo. A substitution of 
sulfate at C-3 position of ǃ-galactosyl residue in T-hapten enhanced its binding efficiency 
about 15 fold towards galectin-4 and 3 fold towards galectin-3 (Ideo et al. 2002). Similarly, 
the studies of our laboratory on galectin specificities showed that 3-O-Sulfo Galǃ1, 4GlcNAc 
as compared to Galǃ1, 4GlcNAc was 3 fold more efficient in binding to galectin-1 (Allen et 
al. 1998). Thus, the enhancement of the binding ability to galectins by 3-O-Sulfation of ǃ-
galactosyl residues appears to be a common characteristic of galectin family. In addition, 3'-
sialylation Core1 in contrast to 3'-sulfated Core1 had very weak affinity for galectin-4 (Ideo 
et al. 2002). Hippo et al. (2001) analyzed six gastric cancer cell lines by Northern Blot and 
observed an up-regulation of galectin-4. Sulfatide was found as a major acidic glycolipid in 
human gastric mucosa (Natomi et al. 1993) and the expression of cerebroside 
sulfotransferase mRNA in endoscopic bioptic specimens of eleven gastric cancer cases was 
reported by Kobayashi et al. (1999). The present study finds several fold consistent increase 
in Gal3Sulfotransferase activity in gastric tumor. The resulting 3-O-Sulfogalactosyl residues 
in gastric tumor cell glycoproteins and glycolipids may facilitate the interaction of gastric 
tumor cells with galectin-4, resulting in intercellular homotypic and heterotypic adhesion of 
gastric cancer cells. 
5. Conclusion 
It becomes evident from the present study that among the various transferases, which can 
modify the terminal Gal residues in carbohydrate chains as shown in Table 2, only 
Gal3Sulfotransferases show a consistent several fold elevated activity in all gastric tumor 
specimens: Gal3-sulfo-T4 (Gal3-sulfortransferase specific for Galǃ1,3GalNAcǂ-O-Ser/Thr) 
and GlcNAc6-Sulfo-T are apparently associated with poorly differentiated gastric 
adenocarcinoma whereas poorly differentiated Signet ring cell gastric carcinoma expresses a 
high level of Gal3Sulfo-T2, a Gal3Sulfotransferase acting on Galǃ1,4GlcNAcǃ- terminal unit. 
The most consistent change in glycosyltransferase activity could be found only with ǂ1, 2-
FT. A significant decrease in this activity was seen in the range 40 – 90% in seven gastric 
tumor specimens. Thus, the present study was able to show that down regulation of ǂ1,2-FT 
activity accompanied by induction of Gal3-O-Sulfotransferase activities acting on Gal 
terminals could be involved in the facile sulfation of carbohydrate chains, which may 
contribute to the microenvironment suitable for interaction with galectin-4 in promoting 
tumor growth and metastasis. Furthermore, the sulfation of Gal terminal as well as GlcNAc 
residues would render the carbohydrate chains strong anionic charge, resistance to 
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degradation by sialidases, galactosidases and hexosaminidases and this would increase their 
half-life in receptor-mediated glycoprotein clearance.  
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